Swiss venture capital firms BioMedPartners and BB Pureos Bioventures have co-led a CHF12.5m ($12.3m) series A round in Alentis Therapeutics, a Swiss-French newco, that is looking to develop novel therapeutics in advanced liver disease and cancer. Other investors in the syndicate are BPI France, Schroder Adveq and the German High-Tech Gründerfonds. Markus Ewert, formerly CBO at Ablynx NV, has been appointed CEO of the new company, which will be headquartered in Basel, Switzerland with a subsidiary in Strasbourg, France and a branch in Germany.
Incubated for the past 18 months by SATT Connectus, the tech transfer accelerator associated with the Alsace region, Alentis is...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
